The first consignment of Covaxin developed by Bharat Biotech is being carried via flight from Hyderabad to Delhi on Wednesday, officials informed.
Speaking to ANI, the official said, "The first consignment of vaccine from Bharat Biotech is being carried by Air India on AI 559 from Hyderabad to Delhi on Wednesday at 0640 hours."
Covishield and Covaxin, the two COVID-19 vaccines which have received Emergency Use Authorisation (EAU) have been tested on thousands of people and side-effects are negligible, Dr VK Paul, Member (Health), NITI Aayog, said on Tuesday and noted that the two "are safest of the vaccines".
"Both the vaccines (Covishield and Covaxin) have been authorized for emergency use and there should be no doubt about their safety. They have been tested on thousands of people and side-effects are negligible. There is no risk of any significance," Dr Paul said at a press conference.
The first phase of the COVID-19 vaccination drive is scheduled to start from January 16.
Health Secretary Rajesh Bhushan said that the Central government is having close collaboration with states and union territories for vaccine roll-out. "All preparations are on track for vaccine roll-out from January 16," he said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU